ANIK
Anika Therapeutics, Inc.
$14.48
-2.10%
$196.8M
No data for this timeframe.
Vol
Market Cap$196.8M
Cap SizeMicro Cap
Inst. Holders8 funds
Inst. Value$24.1M
Inst. Activity5 buys / 0 sells
Insider Activity2B / 0S
Insider Net $$223.2K
SEC Reports6
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0000898437·Prev Close $14.79
Recent Activity
Jun 5, 2026
other
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracke
Jun 1, 2026
SEC
Anika Therapeutics filed a supplement to its proxy statement correcting the disclosure of stock options outstanding unde
DEFA14A — Impact 3/10
May 4, 2026
SEC
Anika Therapeutics insiders (CEO and director) purchased $223K in open-market shares in the week following the Q1 2026 e
CLUSTER — Impact 5/10
May 1, 2026
Insider
HENNEMAN JOHN B III bought 5,000 shares
Director @ $14.66 ($73.3K)
Apr 30, 2026
Insider
Griffin Stephen D. bought 12,200 shares
President and CEO @ $12.29 ($149.9K)
Apr 29, 2026
SEC
Anika Therapeutics reported Q1 2026 revenue of $29.6M, up 13% YoY and beating consensus of $28.1M, but GAAP EPS of -$0.3
8-K — Impact 6/10
Mar 19, 2026
Insider
McLeod Ian sold 13,097 shares
SVP, CAO & Treasurer @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — ADD
772,230 shares ($7.4M)
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$17.50 (Feb 2026)
Current $14.48
Low $17.00
Median $17.50
High $18.00
2 analysts
$17.00
$18.00
Analyst Ratings
3Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 27, 2026 | Barrington Research | MAINTAIN | Outperform → Outperform |
| Jan 9, 2026 | Barrington Research | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.03 ▼ -57.1% | $0.03 — $0.03 | 123% YoY | 1 |
| Next Q | $0.03 ▼ -66.7% | $0.03 — $0.03 | -25% YoY | 1 |
| Current FY | $0.41 ▲ +64.0% | $0.41 — $0.41 | 273% YoY | 1 |
| Next FY | $0.46 ▲ +15.0% | $0.46 — $0.46 | 12% YoY | 1 |
Latest Reports
NEUTRAL
DEFA14A
3/10
Anika Therapeutics filed a supplement to its proxy statement correcting the disclosure of stock options outstanding unde
Jun 1, 2026
MIXED
CLUSTER
5/10
Anika Therapeutics insiders (CEO and director) purchased $223K in open-market shares in the week following the Q1 2026 e
May 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $7.5M | — |
| MORGAN STANLEY | $7.4M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $5.0M | — |
| TWO SIGMA INVESTMENTS, LP | $2.2M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.0M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | HENNEMAN JOHN | BUY | $73.3K |
| Apr 30, 2026 | Griffin Stephen | BUY | $149.9K |
| Mar 19, 2026 | McLeod Ian | A | $0.00 |
| Mar 19, 2026 | McLeod Ian | A | $0.00 |
| Mar 15, 2026 | Blanchard Cheryl | M | $0.00 |
8 institutional holders with $24.1M total value (2,503,401 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, RENAISSANCE. Net buying activity: 5 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 779,165 | $7.5M | 31.1% | — |
| 2 | MORGAN STANLEY | 772,230 | $7.4M | 30.8% | ADD +95.6% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 515,717 | $5.0M | 20.6% | — |
| 4 | TWO SIGMA INVESTMENTS, LP | 233,808 | $2.2M | 9.3% | DOUBLED +192.5% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 106,297 | $1.0M | 4.2% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 48,301 | $464.2K | 1.9% | ADD +62.7% |
| 7 | FMR LLC | 33,208 | $319.1K | 1.3% | ADD +60.1% |
| 8 | WELLS FARGO & COMPANY/MN | 14,675 | $141.0K | 0.6% | ADD +43.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 394,741 | 772,230 | +95.6% | $7.4M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 79,921 | 233,808 | +192.5% | $2.2M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 29,682 | 48,301 | +62.7% | $464.2K | 2025-Q4 |
| FMR LLC | ADD | 20,747 | 33,208 | +60.1% | $319.1K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 10,210 | 14,675 | +43.7% | $141.0K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 108,382 | 394,741 | +264.2% | $3.7M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 79,921 | — | $751.3K | 2025-Q3 |
| UBS Group AG | TRIM | 91,067 | 28,783 | -68.4% | $270.6K | 2025-Q3 |
| FMR LLC | TRIM | 29,075 | 20,747 | -28.6% | $195.0K | 2025-Q3 |
| UBS Group AG | DOUBLED | 14,052 | 91,067 | +548.1% | $963.5K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 189,178 | 124,836 | -34.0% | $1.9M | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 68,724 | 14,052 | -79.6% | $211.2K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 12,096 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | TRIM | 452,977 | 189,178 | -58.2% | $3.1M | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 42,370 | 75,235 | +77.6% | $1.2M | 2024-Q4 |
| UBS Group AG | DOUBLED | 7,540 | 68,724 | +811.5% | $1.1M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 5,662 | 7,421 | +31.1% | $122.2K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 149,956 | — | $3.7M | 2024-Q3 |
5 unique insiders with 2 transactions. Net insider value: $223.2K ($223.2K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | HENNEMAN JOHN B III | Director | BUY | 5,000 | $14.66 | $73.3K |
| Apr 30, 2026 | Griffin Stephen D. | President and CEO | BUY | 12,200 | $12.29 | $149.9K |
| Mar 19, 2026 | McLeod Ian | SVP, CAO & Treasurer | A | 13,097 | $0.00 | $0.00 |
| Mar 19, 2026 | McLeod Ian | SVP, CAO & Treasurer | A | 17,663 | $0.00 | $0.00 |
| Mar 15, 2026 | Blanchard Cheryl R | Director | M | 25,131 | $0.00 | $0.00 |
| Mar 15, 2026 | Blanchard Cheryl R | Director | F | 12,104 | $14.20 | $171.9K |
| Mar 15, 2026 | McLeod Ian | SVP, CAO & Treasurer | M | 2,658 | $0.00 | $0.00 |
| Mar 15, 2026 | McLeod Ian | SVP, CAO & Treasurer | F | 781 | $14.20 | $11.1K |
| Mar 15, 2026 | McLeod Ian | SVP, CAO & Treasurer | M | 2,658 | $0.00 | $0.00 |
| Mar 15, 2026 | Colleran David | EVP, General Counsel, Corp Sec | M | 6,449 | $0.00 | $0.00 |
| Mar 15, 2026 | Colleran David | EVP, General Counsel, Corp Sec | F | 1,893 | $14.20 | $26.9K |
| Mar 15, 2026 | Colleran David | EVP, General Counsel, Corp Sec | M | 6,449 | $0.00 | $0.00 |
| Mar 15, 2026 | Blanchard Cheryl R | Director | M | 25,131 | $0.00 | $0.00 |
| Mar 14, 2026 | Blanchard Cheryl R | Director | M | 24,519 | $0.00 | $0.00 |
| Mar 14, 2026 | McLeod Ian | SVP, CAO & Treasurer | F | 1,449 | $14.20 | $20.6K |
| Mar 14, 2026 | McLeod Ian | SVP, CAO & Treasurer | A | 1,161 | $0.00 | $0.00 |
| Mar 14, 2026 | McLeod Ian | SVP, CAO & Treasurer | M | 3,774 | $0.00 | $0.00 |
| Mar 14, 2026 | McLeod Ian | SVP, CAO & Treasurer | M | 3,774 | $0.00 | $0.00 |
| Mar 14, 2026 | Griffin Stephen D. | President and CEO | A | 6,412 | $0.00 | $0.00 |
| Mar 14, 2026 | Colleran David | EVP, General Counsel, Corp Sec | M | 9,388 | $0.00 | $0.00 |
| Mar 14, 2026 | Colleran David | EVP, General Counsel, Corp Sec | A | 4,694 | $0.00 | $0.00 |
| Mar 14, 2026 | Colleran David | EVP, General Counsel, Corp Sec | F | 4,168 | $14.20 | $59.2K |
| Mar 14, 2026 | Colleran David | EVP, General Counsel, Corp Sec | M | 9,388 | $0.00 | $0.00 |
| Mar 14, 2026 | Griffin Stephen D. | President and CEO | F | 5,944 | $14.20 | $84.4K |
| Mar 14, 2026 | Griffin Stephen D. | President and CEO | M | 12,824 | $0.00 | $0.00 |
| Mar 14, 2026 | Griffin Stephen D. | President and CEO | M | 12,824 | $0.00 | $0.00 |
| Mar 14, 2026 | Blanchard Cheryl R | Director | A | 24,520 | $0.00 | $0.00 |
| Mar 14, 2026 | Blanchard Cheryl R | Director | F | 14,728 | $14.20 | $209.1K |
| Mar 14, 2026 | Blanchard Cheryl R | Director | M | 24,519 | $0.00 | $0.00 |
| Mar 9, 2026 | Colleran David | EVP, General Counsel, Corp Sec | F | 1,919 | $14.96 | $28.7K |
| Mar 9, 2026 | Colleran David | EVP, General Counsel, Corp Sec | M | 5,465 | $0.00 | $0.00 |
| Mar 9, 2026 | Colleran David | EVP, General Counsel, Corp Sec | M | 5,465 | $0.00 | $0.00 |
| Mar 9, 2026 | Blanchard Cheryl R | Director | M | 20,001 | $0.00 | $0.00 |
| Mar 9, 2026 | McLeod Ian | SVP, CAO & Treasurer | M | 2,197 | $0.00 | $0.00 |
| Mar 9, 2026 | McLeod Ian | SVP, CAO & Treasurer | F | 639 | $14.96 | $9.6K |
| Mar 9, 2026 | McLeod Ian | SVP, CAO & Treasurer | M | 2,197 | $0.00 | $0.00 |
| Mar 9, 2026 | Blanchard Cheryl R | Director | F | 5,871 | $14.96 | $87.8K |
| Mar 9, 2026 | Blanchard Cheryl R | Director | M | 20,001 | $0.00 | $0.00 |
| Feb 1, 2026 | Griffin Stephen D. | President and CEO | A | 310,207 | $0.00 | $0.00 |
| Feb 1, 2026 | Griffin Stephen D. | President and CEO | A | 130,402 | $0.00 | $0.00 |
6 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 3 mixed, 3 neutral. Avg impact: 4.2/10.
NEUTRAL
DEFA14A
3/10
Anika Therapeutics filed a supplement to its proxy statement correcting the disclosure of stock opti
Jun 1, 2026
MIXED
CLUSTER
5/10
Anika Therapeutics insiders (CEO and director) purchased $223K in open-market shares in the week fol
May 4, 2026
MIXED
8-K
6/10
Anika Therapeutics reported Q1 2026 revenue of $29.6M, up 13% YoY and beating consensus of $28.1M, b
Apr 29, 2026
NEUTRAL
DEFA14A
2/10
Anika Therapeutics filed a DEFA14A (additional definitive proxy soliciting materials) with no substa
Apr 28, 2026
NEUTRAL
PRESS-RELEASE
3/10
Anika Therapeutics announced it will release Q1 2026 financial results on April 29, 2026, ahead of m
Apr 15, 2026
MIXED
8-K
6/10
Anika Therapeutics reported flat Q4 revenue of $30.6M but full-year 2025 revenue declined 6% to $112
Feb 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Feb 2026): 88% buy across 8 analysts — 3 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$17.50 mean target (Feb 2026)
$17.00 Low
$18.00 High
| Metric | Value |
|---|---|
| Current Price | $14.48 |
| Target Low | $17.00 |
| Target Mean | $17.50 |
| Target Median | $17.50 |
| Target High | $18.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.03 | $0.03 | $0.03 | 123.1% | -57.1% | 0↑ 1↓ | $0.0B | 3.5% | 1 |
| Next Q 2026-09-30 |
$0.03 | $0.03 | $0.03 | -25.0% | -66.7% | 0↑ 1↓ | $0.0B | 5.4% | 1 |
| Current FY 2026-12-31 |
$0.41 | $0.41 | $0.41 | 272.7% | +64.0% | 0↑ 1↓ | $0.1B | 5.1% | 1 |
| Next FY 2027-12-31 |
$0.46 | $0.46 | $0.46 | 12.2% | +15.0% | 1↑ 0↓ | $0.1B | 6.7% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.030 | |
| 7d ago | $0.070 | -0.040 |
| 30d ago | $0.070 | -0.040 |
| 60d ago | $0.070 | -0.040 |
| 90d ago | $0.070 | -0.040 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 27, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Jan 9, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 5, 2026
other
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=c01BYhTYq6orCPlUpNrw-c1u-UPDWTkeerfy_E51pNQ
Apr 29, 2026
earnings
Anika Reports First Quarter 2026 Financial Results
<p align="center">Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing</p>
Apr 29, 2026
earnings_calendar
ANIK Q1 2026 Earnings Scheduled — 2026-04-29
Apr 15, 2026
earnings
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
<p>BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=STMAgvvRjgtvTtJmT0W03vuGgVJGeFOS0wBSjIfHmi
Apr 3, 2026
activist
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>BEDFORD, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=-8DvG-AumDrj8YuqXAOoyS2Yc0HUn4pIKZDSY-MkoP
Feb 26, 2026
earnings_calendar
ANIK Q4 2025 Earnings Before Market Open — 2026-02-26